CPA
RAPT

Capital Performance Advisors’s RAPT Therapeutics RAPT Stock Holding History

Capital Performance Advisors’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4
Closed -$68 – 2079
2024
Q3 		$68 Buy
+4
New +$81 ﹤0.01% 2760

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Performance Advisors's RAPT Position: Q4 2024 in Review

Capital Performance Advisors sold out of RAPT Therapeutics (RAPT) in Q4 2024, closing a stake of 4 shares — an estimated $68 sold.

Capital Performance Advisors first reported a position in RAPT in Q3 2024 and held it in 1 quarter. The position peaked at $68 in Q3 2024. 91 funds tracked by Wall St. Rank hold RAPT as of Q4 2024.

  • Capital Performance Advisors reported no remaining RAPT Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 4 RAPT Therapeutics shares in Q4 2024, an estimated $68.
  • Capital Performance Advisors first reported a position in RAPT Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's RAPT Therapeutics position peaked at $68 in Q3 2024.
  • 91 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.